我们用随机对照临床试验研究拉米夫定对乙型肝炎肝硬化的疗效现报道如下。1.资料与方法:89例慢性乙型肝炎肝硬化失代偿患者,诊断符合2000年病毒性肝炎诊断标准[1]。血清定量PCR法测定HBV DNA均阳性,年龄16-65岁,Child-pugh分级在A、B级。排除标准:肝性脑病、原发性肝癌、血清胆红素>85 μmol/L、Ⅲ型腹水和肾功能不全者、血清丙型肝炎病毒或丁型肝炎病毒阳性、血小板计数<80 ×109/L或粒细胞计数<1.5 ×109/L酗酒者和不稳定糖尿病患者。随机分为两组,拉米夫定治疗组49例,其中HBeAg阳性29例,阴性20例;Child A级13例,B级36例。对照组40 We use randomized controlled clinical trials of lamivudine efficacy of hepatitis B cirrhosis are reported below. 1 Materials and Methods: 89 cases of chronic hepatitis B patients with decompensated liver cirrhosis, diagnosis consistent with the 2000 diagnostic criteria of viral hepatitis [1]. Serum quantitative PCR assay for HBV DNA were positive, aged 16-65 years old, Child-pugh grading in the A, B grade. Exclusion criteria: hepatic encephalopathy, primary liver cancer, serum bilirubin> 85 μmol / L, type Ⅲ ascites and renal insufficiency, positive for hepatitis C virus or hepatitis D virus, platelet count <80 × 109 / L or granulocyte count <1.5 × 109 / L in alcoholics and unstable diabetic patients. Randomly divided into two groups, lamivudine treatment group of 49 cases, of which 29 cases of HBeAg positive, negative in 20 cases; Child A grade in 13 cases, B grade 36 cases. Control group 40